John Liatos insider trades: Kintara Therapeutics (KTRA) SEC Form 4 filings

About John Liatos's insider trades

John Liatos is SVP, Business Development at Kintara Therapeutics (KTRA). John has not reported an open-market purchase or sale.

Their filings also include grants and awards (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KTRA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.